Licensed Formulation Patents definition

Licensed Formulation Patents means any Patent claiming priority to U.S. patent application serial no. [***] related to the Licensed Compound [***]. For clarity, Licensed Formulation Patents are included in Non-Exclusive Licensed Patents, unless Licensee exercises the Option in Section 2.1(iii), in which case Licensed Formulation Patents are included in the Exclusive Licensed Patents.
View Source
Licensed Formulation Patents means the Patent Rights Controlled by UCB as of the Effective Date that cover the formulation of the Compound and/or the Licensed Product, along with any future Patent Rights issuing from such Patent Rights or claiming priority to such Patent Rights. The Licensed Formulation Patents existing on the Effective Date are listed in Schedule 3.
View Source
Licensed Formulation Patents means any Patent claiming priority to U.S. patent application serial no. [***] related to the Licensed Compound [***]. For clarity, Licensed Formulation Patents are included in Non-Exclusive Licensed Patents, unless Licensee exercises the Option in Section 2.1(iii), in which case Licensed Formulation Patents are included in the Exclusive Licensed Patents. Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. Confidential Treatment Requested by Kiniksa Pharmaceuticals, Ltd.
View Source

Examples of Licensed Formulation Patents in a sentence

  • Upon MedImmune’s receipt of such written notice, MedImmune and Licensee shall cooperate with each other to take steps to file, if it has not already been done, a portfolio of Licensed Formulation Patents from the Non-Exclusive Licensed Patents that claim priority to U.S. patent application serial no.

  • Upon Licensee’s exercise of the Option, (a) all Licensed Formulation Patents shall be deemed Exclusive Licensed Patents, and (b) MedImmune and its Affiliates shall not prepare, file or prosecute patent claims that specifically relate to, or otherwise recite, the Licensed Compound in any Patents that claim priority directly or indirectly to U.S. patent application serial no.

  • MedImmune shall consider in good faith the requests and suggestions of Licensee with respect to filing the portfolio of Licensed Formulation Patents; provided, however, that Licensee shall have the right to select in which jurisdictions in the Territory the Licensed Formulation Patents shall be filed.

  • UCB will also retain all rights under the Licensed Compound Patents, Licensed Formulation Patents, Licensed Compound Know-How and Licensed Manufacturing IP that are not expressly granted to Company (including, without limitation, all rights outside of the Field), and shall have the right to grant further licenses to Third Parties with respect to such retained rights, subject to any restrictions set forth in Section 2.8(a) and (b).

  • UCB hereby grants to Company a non-exclusive, royalty-bearing license or sublicense (as applicable) under and to the Licensed Formulation Patents and UCB’s rights, title and interest in the Licensed Manufacturing IP to make, have made, use, import, export, offer for sale and sell the Compound and Licensed Products (but no other compounds or products) in the Field in the Territory ***.

  • The JPC shall be responsible for developing a patent strategy for the Licensed Product, including making key decisions on drafting, filing, prosecution and maintenance of the Licensed Compound Patents and Licensed Formulation Patents, as well as providing a forum for the Parties to discuss material issues and provide input to each other regarding the Licensed Compound Patents and Licensed Formulation Patents.

  • Each Party shall promptly notify the other Party in writing if it becomes aware of any Third Party actions which may constitute misappropriation or unauthorized use of the Licensed Compound Know-How and/or any Licensed Manufacturing Know-How, infringement of the Licensed Compound Patents, Licensed Formulation Patents and/or Licensed Manufacturing IP, or a claim to invalidate or contest the enforceability of one or more such patents.

  • In the event that *** decides to not pursue, or to abandon or otherwise cease to maintain, one or more patents that constitute Licensed Compound Patents or Licensed Formulation Patents in a given country or countries, it will notify *** to that effect, which notice shall be at least *** in advance of any prosecution deadline.

  • Through the JPC, *** shall keep *** advised of the status of the actual and prospective patent applications and issued patents that are within the scope of the Licensed Compound Patents and the Licensed Formulation Patents, and shall *** may have in relation to such activities and, with respect to the Licensed Compound Patents, shall ***.

  • The Fixed Rate shall apply to such amounts converted until a date determined by RTFC and agreed to by Borrower (the "Adjustment Date").